Lv51
835 积分 2020-08-23 加入
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
10小时前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
10小时前
已完结
OA06.01 A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC
1天前
求助中
LBA11 A phase II clinical study of dose optimization for ZG006 (Alveltamig) in patients with advanced small cell lung cancer who have received at least two prior lines of therapy (ZG006-002)
1天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
3天前
已完结
Abstract 1587: A novel dual-payload HER3-directed antibody-drug conjugate, shows potent antitumor efficacy in HER3-low in vivo tumor models
7天前
已完结
Transferrin receptor–targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA
13天前
已完结
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
13天前
已完结
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
19天前
已完结
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
19天前
已完结
皖公网安备34019202002308
